Smith & Nephew SNATS, Inc. $SNN Position Boosted by Cetera Investment Advisers

Cetera Investment Advisers raised its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 8.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,748 shares of the medical equipment provider’s stock after acquiring an additional 1,373 shares during the quarter. Cetera Investment Advisers’ holdings in Smith & Nephew SNATS were worth $475,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Hara Capital LLC increased its holdings in Smith & Nephew SNATS by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares during the last quarter. Raymond James Financial Inc. bought a new position in Smith & Nephew SNATS during the fourth quarter valued at approximately $4,992,000. Sterling Capital Management LLC bought a new position in Smith & Nephew SNATS during the fourth quarter valued at approximately $265,000. Townsquare Capital LLC raised its position in Smith & Nephew SNATS by 19.0% during the fourth quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider’s stock valued at $432,000 after acquiring an additional 2,798 shares in the last quarter. Finally, Barclays PLC bought a new position in Smith & Nephew SNATS during the fourth quarter valued at approximately $431,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Down 1.1%

Shares of SNN stock opened at $36.20 on Monday. Smith & Nephew SNATS, Inc. has a 12 month low of $23.69 and a 12 month high of $36.84. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The business’s 50 day moving average is $31.24 and its two-hundred day moving average is $28.87. The company has a market cap of $15.85 billion, a PE ratio of 16.76, a price-to-earnings-growth ratio of 1.00 and a beta of 0.68.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be given a $0.285 dividend. This represents a dividend yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio is currently 41.20%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SNN shares. HSBC lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. Canaccord Genuity Group raised their price objective on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a “hold” rating in a research report on Thursday, May 1st. Finally, Hsbc Global Res lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.